THE BIOMATRIX ALPHA REGISTRY1
First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent
Primary Endpoint Major adverse cardiac events (MACE) composite of cardiac death, myocardial infarction (Q-wave and non-Q-wave),or clinically driven target vessel revascularization (TVR) at 9 months.
Results at 9 months
Results at 24 months
LEADERS2 the first all comers trial of PCI
(Limus Eluted from A Durable versus ERodable Stent coating)
Clinical benefit shown in patients undergoing complex PCI2
Results 3 years4:
COMFORTABLE AMI 2 year follow-up5
Thus, BioMatrix has become the Gold Standard in biodegradable technology.